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Vitamin B,,-responsive methylmalonic aciduria is characterized by deficient synthesis of adenosylcobalamin (AdoCbl) and decreased activity of the AdoCbl-dependent mitochondria1 enzyme, methylmalonylCoA mutase. Two distinct disorders of AdoCbl synthes~zed have been characterized (cblA and cblB) and they can be distinguished on the basis of somatic cell complementation analysis. Such studies have clinical usefulness because in general cblA patients have a better prognosis than do cblB patients. We reported a patient whose fibroblasts had the clinical and biochemical features of the cblA class but complemented cells from all known inborn errors of cobalamin metabolism that cause methylmalo~c aciduria, including cbIA. The disorder in this patient was designated as cblA variant. Cells from this patient were tested against a panel of 29 cell lines from cblA patients and complemented all members of this panel. These studies strongly suggest that this patient represents a novel complementation class which we have called cblH. Detailed complementation analysis of a panel of 10 cblA lines provided evidence of interallelic complementation. The presence of this interallelic complementation indicates that care must be taken in the use of complementation analysis to identify cblA patients. These studies suggest that additional biochemical steps are required for the reduction and adenosylation of cobalamin. The full clinical spectrum of the new cblH class and its implications remains to be defined. result from partial deficiencies of either elemon bansfer flavopmtein or its dehydrogenase and have highly variable clinical presentations and often ephemeral metabolite excretion. Direct assay of these latter two enzymes is diff~cult and performed at only a few laboratories worldwide The clinical, biochemical. enzymatic, and molecular variation in SCAD is great and wmplicated by the presence of hvo common allelic variants. 625GlA and 5 I ICK, whose effects on enzymatic activities are not fully understood Quantitation of urine organic acids, plasma acyl-carnitines and urinary acyl-glycines may not sufice to clearly identify patients with these disordtm due to variations in clinical stabs. subshate flux into 241 NIA the panially impaired pathways, and genetic betaogeneity. Therefore, we have modifled an existing doHPLC method for analysis of acyl-)Hamitine esters in skin fibroblasts to optimi~e d a d o n of these disorders (Schmidt-Sommofcld et al Pediatr Res. 44 210. 1998) Incubating fibroblasts with the branched-chain amino 755 Normal acids, leucine, isoleucine and valiie, as well as palmitate, improves detection of the mild GAIl variants; the propionylsamiline to isovaleryva-methyl butyql-carnitine ratio is a very sensitive index of impaired dehydrogenation of the branched chain acyl-CoAs. For SCAD and its variants, butyryl-carnitine wntent is a very sensitive measure of SCAD-mediated bum)-CoA dehydmgenation in mtaa cells Ln normal cells, bulyqlcdmitine content is less than 2% of total cellular acylcamitine content, while it ranges from 10 to 25% in well defied SCAD cases lacking enzyme activity, antigen and harboring two pathogenetic mutations. In addition, we are routinely identifying patients who have clearly impaired SCAD activity, as judged by fibroblast buty@-camitine acauoulations of 4 to 8%. who probably represent genetic compounds for the 625NG and 51 1CiT variant alleles andlor otha pathogenetic mutations. RadioHPLC analysis of fibroblast acyl-camitines permits uniform, optimal challenging of the metabolic pathways in questioq while minimizing the metabolite variation seen in plasma and urine analyses h m patients with varying clinical, metabolic and molecular mnditions. It i s an important adjunct to the laboratory diagnosis of the fatly acid oxidation disorders.

The detection of carbohydrate deficient glycoprotein syndrome by capillary electrophoresis. H. A. Taylor. Greenwood Genetic Center, Greenwood, SC.
Carbohydrate deficient glycoprotein syndrome (CDGS), which was first reported by Jaeken et al. In 1980, is a d~sorder In which many glycoproteins are deficient or have reduced carbohydrate side chains. Many subtypes of CDGS have been described based on the isoelectrophoretic patterns of transferrin and on clinical features. Different enzyme defic~encies have been reported in at least four of the subtypes.
Transfenin is a major serum glycoprotein utilized in the diagnosis of CDGS. It has two carbohydrate side chains each ending with two sialic acids. CDGS patients lack portions of these side chains caustng different transferrin isoforms. These isoforms can be separated by isoelectr~c focusing which has been the method of choice for diagnosing these disorders. Capillary electrophoresis can also be used for detecttng the aberrant transferrin isoforms in CDGS.
Serum of patients previously diagnosed with CDGS (types la, Ib.
and IV) was separated by capillary electrophoresis. The transferrin pattern in CDGS patients is easily distinguished from controls in that tetrasialotransfenin is the predominant isoforrn in normal serum, while in the patient samples both tetra-and disialotransfemn are detected. Capillary electrophoresis. which takes considerably less time and costs much less than the current methods. is a good choice for detecting patients with CDGS.
